
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
Location: United States, California, La Jolla
Employees: 11-50
Total raised: $36M
Founded date: 2007
Investors 5
Date | Name | Website |
- | Bioscience... | bioscience... |
- | Valence Li... | valencefun... |
30.08.2023 | OrbiMed | orbimed.co... |
- | Quark Vent... | quarkventu... |
- | Golden Fal... | falconcapi... |
Funding Rounds 2
Date | Series | Amount | Investors |
11.03.2021 | Series D | $21M | - |
25.05.2020 | Series C | $15M | - |
Persons 1
Date | First Name | Last Name | Title | |||
- | Daniel | Geffken | Interim Ch... | linkedin.c... | - | - |
Mentions in press and media 11
Date | Title | Description |
14.11.2024 | Insiders Bet Big on These Small Cap Stocks Insiders are buying stocks like CalciMedica and BKV Corporation because they have value and catalysts in 2025 to drive higher share prices. | Small-cap stocks are more important than ever. The combined forces of falling interest rates and business-friendly presidential policies are expected to create economic tailwinds in 2025 and a broadening stock market rally including small ... |
09.09.2021 | CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways | |
02.06.2021 | CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study | |
11.03.2021 | CalciMedica Announces $21 Million Series D Financing | Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Za... |
11.03.2021 | CalciMedica has raised a $21M Series D to advance their anti-inflamatory therapy currently being evaluated for severe and critical COVID-19 Pneumonia and acute pancreatitis with SIRS | - |
25.05.2020 | CalciMedica Raises $15M in Series C Financing | CalciMedica Inc., a La Jolla, Calif.-based clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, raised $15m in Series C financing. The ... |
22.05.2020 | CalciMedica Raises $15M in Series C Financing | - |
15.12.2009 | CalciMedica Closes Second Tranche of $12M Series C Financing | CalciMedica, a La Jolla, California-based biotechnology company dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases, announced the closing of the second tranche ... |
12.02.2008 | Life sciences briefing: Tuesday, Feb. 12, 2008 | TODAY’S HEADLINES: Metabolic-disease biotech NGM Biopharma raises $25M (peHUB) Heart, HIV drug maker Numerate acquires assets of Pharmix (release) Next-gen sequencer VisiGen promises $1,000 genome by late 2009 (Genome Technology) CalciMedic... |
31.07.2007 | CalciMedica raises $1.5M for inflammatory disease | CalciMedica, a San Diego biotech focused on autoimmune and inflammatory disease, raised $1.53 million in a first funding round, PE Hub reports, citing a regulatory filing. S.R. One provided the funding. VentureBeat VentureBeat's mission is ... |
Show more